FDA OKs Keytruda Combo for Lung Cancer

The U.S. FDA has approved Merck’s Keytruda in combination with chemotherapy for previously untreated advanced lung cancer.

This approval is being heralded as a “game-changer” for Keytruda, solidifying Merck’s position in the oncology market. The approval was based on data from a study of 123 previously untreated patients with metastatic non-squamous non-small cell lung cancer (NSCLC).

Keytruda carries a host of previous approvals for treating lung, head and neck cancers, melanoma, and, most recently, blood cancer.

Read the press release